Evidence map›Paper›PMID 40486468›Full record

ArticleCureus2025

Durable Response Following the Discontinuation of Immune Checkpoint Inhibitor Therapy in Advanced Non-small Cell Lung Cancer.

Taiyo Nakamura, Yohei Kawaguchi, Jiyunichirou Oosawa, Kentaro Imai, Takuya Aoki, Naohiro Kajiwara, Norihiko Ikeda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Taiyo NakamuraDepartment of Thoracic Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, JPN.
Yohei KawaguchiDepartment of Surgery, Tokyo Medical University, Tokyo, JPN.
Jiyunichirou OosawaDepartment of Thoracic Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, JPN.
Kentaro ImaiDepartment of Thoracic Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, JPN.
Takuya AokiDepartment of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Hachioji, JPN.
Naohiro KajiwaraDepartment of Thoracic Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, JPN.
Norihiko IkedaDepartment of Surgery, Tokyo Medical University, Tokyo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The optimal duration of immune checkpoint inhibitor (ICI) therapy for maximum benefits remains unclear. Recently, the long-term follow-up data from clinical trials suggest the existence of a durable response (DR) that maintains the therapeutic effect even after ICI discontinuation. The study aimed to explore how the characteristics of ICI therapy influence the effectiveness of subsequent treatments in patients with advanced non-small-cell lung cancer (NSCLC). Methods The medical records of 134 patients with NSCLC who received ICIs before December 31, 2022, were retrospectively reviewed. We evaluated the impact of pretreatment ICIs on survival after completion of ICI administration. Results Among the 116 included patients, long ICI use (≥180 days) was the only independent prognostic factor for post-ICI overall survival (OS) in the multivariate analysis (HR: 0.382, 95% CI: 0.206-0.708,

Indexed as

best supportive careimmune checkpoint inhibitorimmune-related adverse eventsnon-small cell lung cancersubsequent chemotherapythe optimal duration of ici therapy

Identifiers

PMID40486468
PMCPMC12141771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.